Prospective comparison of histologic outcomes between 22G and 25G acquire FNA needle for pancreatic/peripancreatic mass
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0003834
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
1. Patients older than 18 years and younger than 80 years
2. Patients with solid pancreatic/peripancreatic mass which is needed pathologic confirmation
Exclusion Criteria
1. cystic pancreatic lesions without the evidence of solid component suspected with malignant transformation
2. cardiopulmonary instability
3. severe coagulopathy (international normalized ratio > 1.5 or platelet count < 50,000 cells/cubic millimeter [cmm3])
4. inability to suspend antithrombotic therapy
5. pregnancy
6. Patients with underlying co-morbidities preclude sedation
7. GI obstruction or previous stomach surgery that preclude EUS examination
8. refusal to provide informed consent or participate in the study.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the procurement rates of histologic cores that the cyto-pathologist considered to be of optimal quality for histological evaluation
- Secondary Outcome Measures
Name Time Method diagnostic performance: diagnostic accuracy, sensitivity, specificity, positive predictive value, negative predictive value